数据显示，中欧基金旗下1只基金位居广生堂十大流通股东。中欧医疗健康混合A（003095）三季度减 持113.65万股，持有股数70.81万股，占流通股的比例为0.52%。根据测算，今日浮盈赚取约317.96万 元。 1月5日，广生堂涨5.04%，截至发稿，报93.64元/股，成交2.59亿元，换手率2.07%，总市值149.14亿 元。 资料显示，福建广生堂药业股份有限公司位于福建省福州市闽侯县福州高新区乌龙江中大道7号海西高 新技术产业园创新园二期16号楼，成立日期2001年6月28日，上市日期2015年4月22日，公司主营业务涉 及核苷类抗乙肝病毒药物的研发、生产与销售。主营业务收入构成为：肝胆疾病药物98.54%，其他(补 充)1.46%。 从广生堂十大流通股东角度 赵磊累计任职时间186天，现任基金资产总规模329.54亿元，任职期间最佳基金回报1.48%， 任职期间 最差基金回报-2.51%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 ...

Core Viewpoint - The introduction of the new performance assessment guidelines for fund managers aims to tightly link their compensation to both relative and absolute performance, with a significant focus on ensuring that investors earn returns [3][4]. Group 1: New Regulations and Impact - The new guidelines stipulate that fund managers who underperform their benchmarks by more than 10% over three years and incur losses will face a salary reduction of at least 30% [3][4]. - Approximately 30% of active equity fund managers may hit the "30% salary reduction" threshold due to poor performance [5][10]. - The ultimate goal of the regulations is to align the interests of fund managers with those of investors, ensuring that investors genuinely profit from their investments [4]. Group 2: Performance Statistics - Data shows that nearly 60% of funds have failed to outperform their benchmarks over the past three years, with only 44% of the 3,794 funds analyzed achieving this [6]. - Among these, 1,394 funds have underperformed their benchmarks by over 10%, representing nearly 37% of the total sample [7]. - The analysis indicates that around 34% of funds not only underperformed but also had negative profit margins, failing to generate positive returns for investors [10]. Group 3: Notable Fund Managers and Cases - Several prominent fund managers, such as Lu Bin and Shi Cheng, have multiple funds that have triggered the salary reduction criteria, with all their managed products underperforming significantly [15][16]. - Lu Bin's funds have consistently underperformed, with all seven products managed by him failing to meet benchmarks over the past three years [16]. - Shi Cheng's strategy of heavily investing in a single sector (new energy) led to significant gains during a bull market but resulted in substantial losses as market conditions changed, highlighting the risks of concentrated investment strategies [21][22].

Core Points - On November 19, Angli康's stock dropped by 5.16%, trading at 40.47 CNY per share, with a transaction volume of 484 million CNY and a turnover rate of 6.31%, resulting in a total market capitalization of 8.164 billion CNY [1] - Angli康, established on December 30, 2001, and listed on October 23, 2018, is primarily engaged in the research, production, and sales of chemical raw materials and formulations, with its main revenue sources being formulations (43.46%), raw materials (39.82%), specialty intermediates (12.44%), others (3.72%), and pharmaceutical excipients (0.56%) [1] Shareholder Analysis - Among Angli康's top ten circulating shareholders, a fund under China Europe Fund holds a significant position. The China Europe Medical Health Mixed A Fund (003095) reduced its holdings by 3.351 million shares in the third quarter, now holding 3.0863 million shares, which accounts for 1.67% of the circulating shares. The estimated floating loss today is approximately 6.7899 million CNY [2] - The China Europe Medical Health Mixed A Fund (003095) was established on September 29, 2016, with a current scale of 16.977 billion CNY. Year-to-date returns are 20.05%, ranking 4065 out of 8138 in its category; the one-year return is 16.2%, ranking 4684 out of 8055; and since inception, the return is 107.2% [2] Fund Manager Information - The fund managers of the China Europe Medical Health Mixed A Fund (003095) are Ge Lan and Zhao Lei. As of the report, Ge Lan has a cumulative tenure of 10 years and 298 days, with the fund's total asset scale at 43.544 billion CNY, achieving the best return of 107.89% and the worst return of -35.13% during her tenure [3] - Zhao Lei has a cumulative tenure of 139 days, with the fund's total asset scale at 32.954 billion CNY, achieving the best return of 8.11% and the worst return of 7.8% during his tenure [3]

Core Viewpoint - Jiuzhou Pharmaceutical has seen a significant stock price increase, with a 5.31% rise on November 14, reaching 21.42 yuan per share, and a total market capitalization of 19.052 billion yuan, indicating strong investor interest and performance in the market [1]. Company Overview - Jiuzhou Pharmaceutical, established on July 13, 1998, and listed on October 10, 2014, is located in Taizhou, Zhejiang Province. The company specializes in the research, production, and sales of chemical raw materials and pharmaceutical intermediates [1]. - The revenue composition of Jiuzhou Pharmaceutical includes 79.81% from new drug custom development and manufacturing services (CDMO), 18.22% from specialty raw materials and intermediates, and 1.96% from other sources [1]. Shareholder Insights - Among the top circulating shareholders of Jiuzhou Pharmaceutical, a fund under China Europe Fund has increased its holdings. The China Europe Medical Health Mixed A Fund (003095) added 3.9767 million shares in the third quarter, bringing its total to 17.403 million shares, which represents 1.96% of the circulating shares [2]. - The fund has realized a floating profit of approximately 18.7952 million yuan today, with a total floating profit of 15.8367 million yuan during the four-day stock price increase [2]. Fund Manager Performance - The fund manager of China Europe Medical Health Mixed A, Ge Lan, has a tenure of 10 years and 293 days, with a total fund size of 43.544 billion yuan. The best return during her tenure is 109.26%, while the worst is -35.13% [3]. - Co-manager Zhao Lei has been in position for 134 days, managing a fund size of 32.954 billion yuan, with a best return of 8.82% and a worst return of 8.51% during his tenure [3].

Group 1 - The core point of the article highlights the recent performance of Guangshentang, which saw a 5.03% increase in stock price, reaching 109.55 CNY per share, with a trading volume of 812 million CNY and a turnover rate of 5.70%, resulting in a total market capitalization of 17.448 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. is based in Fuzhou, Fujian Province, and specializes in the research, production, and sales of nucleoside antiviral drugs for hepatitis B, with 98.54% of its revenue coming from liver and gallbladder disease medications [1] Group 2 - Among the top ten circulating shareholders of Guangshentang, a fund under China Europe Fund, specifically the China Europe Medical Health Mixed A (003095), reduced its holdings by 1.1365 million shares in the third quarter, now holding 708,100 shares, which accounts for 0.52% of the circulating shares, with an estimated floating profit of approximately 3.7178 million CNY [2] - The China Europe Medical Health Mixed A fund was established on September 29, 2016, with a current scale of 16.977 billion CNY, achieving a year-to-date return of 21.25% and a one-year return of 8.97% [2]

Group 1 - The core viewpoint of the news is that Guangshentang's stock price increased by 5.82%, reaching 108.92 CNY per share, with a trading volume of 916 million CNY and a turnover rate of 6.61%, resulting in a total market capitalization of 17.347 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. is located in Fuzhou, Fujian Province, and was established on June 28, 2001, with its listing date on April 22, 2015. The company specializes in the research, production, and sales of nucleoside antiviral drugs for hepatitis B [1] - The main business revenue composition of Guangshentang is 98.54% from liver and gallbladder disease drugs and 1.46% from other supplementary products [1] Group 2 - From the perspective of the top ten circulating shareholders, a fund under China Europe Fund ranks among Guangshentang's top shareholders. The China Europe Medical Health Mixed A Fund (003095) reduced its holdings by 1.1365 million shares in the third quarter, now holding 708,100 shares, which accounts for 0.52% of the circulating shares [2] - The estimated floating profit for the China Europe Medical Health Mixed A Fund today is approximately 4.2418 million CNY [2] - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, with a latest scale of 16.977 billion CNY. Year-to-date returns are 21.33%, ranking 4326 out of 8147 in its category, while the one-year return is 10.73%, ranking 5278 out of 8056 [2]

Group 1 - The core point of the news is that Guangshentang's stock price dropped by 5.09% to 102.88 CNY per share, with a trading volume of 722 million CNY and a turnover rate of 5.01%, resulting in a total market capitalization of 16.385 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. is located in Fuzhou, Fujian Province, and was established on June 28, 2001, with its listing date on April 22, 2015. The company specializes in the research, production, and sales of nucleoside antiviral drugs for hepatitis B [1] - The main business revenue composition of Guangshentang is 98.54% from liver and gallbladder disease drugs and 1.46% from other supplementary products [1] Group 2 - Among the top ten circulating shareholders of Guangshentang, a fund under China Europe Fund holds a position. The China Europe Medical Health Mixed A Fund (003095) reduced its holdings by 1.1365 million shares in the third quarter, now holding 708,100 shares, which accounts for 0.52% of the circulating shares [2] - The estimated floating loss for the China Europe Medical Health Mixed A Fund today is approximately 3.909 million CNY. The fund was established on September 29, 2016, with a latest scale of 16.977 billion CNY, and has achieved a year-to-date return of 21.69% [2] - The fund's one-year return is 13.44%, ranking 5002 out of 8053 in its category, while since its inception, it has achieved a return of 110.03% [2]

Group 1 - The core point of the news is that Guangshentang's stock price dropped by 5.03% to 113.01 CNY per share, with a trading volume of 925 million CNY and a turnover rate of 5.80%, resulting in a total market capitalization of 17.999 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. is located in Fuzhou, Fujian Province, and was established on June 28, 2001, with its listing date on April 22, 2015. The company primarily focuses on the research, production, and sales of nucleoside antiviral drugs for hepatitis B [1] - The main business revenue composition of Guangshentang is 98.54% from liver and gallbladder disease drugs and 1.46% from other supplementary products [1] Group 2 - Among the top ten circulating shareholders of Guangshentang, a fund under China Europe Fund holds a position. The China Europe Medical Health Mixed A Fund (003095) reduced its holdings by 1.1365 million shares in the third quarter, now holding 708,100 shares, which accounts for 0.52% of the circulating shares [2] - The estimated floating loss for the China Europe Medical Health Mixed A Fund today is approximately 4.2418 million CNY [2] - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, with a current scale of 16.977 billion CNY. Year-to-date returns are 25.14%, ranking 3731 out of 8150 in its category, while the one-year return is 20.3%, ranking 4361 out of 8043 [2]

Group 1 - Core viewpoint: Huadong Medicine (000963.SZ) reported its Q3 2025 results, highlighting significant institutional ownership and changes in shareholding among various funds and investors [1][2][3] Group 2 - As of October 27, 2025, 32 institutional investors held a total of 1.205 billion shares of Huadong Medicine, representing 68.71% of its total share capital [1] - The top ten institutional investors collectively held 67.93% of the shares, with an increase of 0.71 percentage points compared to the previous quarter [1] - In the public fund sector, 10 funds increased their holdings, while 8 funds reduced their holdings, with a decrease of 0.50% in the latter category [2] - One social security fund, the National Social Security Fund 112 Portfolio, reported a slight decrease in holdings [2] - In the insurance sector, one insurance company increased its holdings by 0.3%, while one new insurance investor was disclosed [3] - Foreign investment saw an increase from one foreign fund, Hong Kong Central Clearing Limited, with a rise of 0.69% in holdings [3]

Core Insights - Angli康 (002940.SZ) reported its Q3 2025 results, revealing that as of October 24, 2025, nine institutional investors held a total of 94.36 million shares, representing 46.77% of the company's total equity [1] - The institutional holding percentage decreased by 7.00 percentage points compared to the previous quarter [1] Institutional Holdings - The institutional investors include Shenzhou JunTai Investment Co., Ltd., Zhejiang Angli康 Pharmaceutical Co., Ltd. - Phase I Employee Stock Ownership Plan, and several funds from major banks such as Bank of China, Industrial and Commercial Bank of China, and China Construction Bank [1] - The total institutional holding percentage is now at 46.77%, down from the previous quarter [1] Public Fund Holdings - Four public funds increased their holdings this period, including Huatai-PB Innovation Medicine Mixed A, GF Healthcare Stock A, and others, with an increase rate of 1.45% [2] - One public fund, China Europe Medical Health Mixed A, reported a decrease in holdings by 1.66% compared to the previous quarter [2] - One new public fund was disclosed this period, namely Longcheng Pharmaceutical Industry Selected Mixed Initiation A [2] - A total of 114 public funds were not disclosed this period, including notable funds like GF Technology Innovation Mixed A and others [2]